-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: IK-175 (KYN-175) was under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: IK-175 (KYN-175) was under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KHK-2455 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KHK-2455 in Solid Tumor Drug Details: KHK-2455 is under development for the treatment of head...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Non-Small Cell Lung Cancer Drug Details: IK-175 (KYN-175) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Ovarian Cancer Drug Details: IK-175 (KYN-175) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Pancreatic Cancer Drug Details: IK-175 (KYN-175) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Colon Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Colon Cancer Drug Details: IK-175 (KYN-175) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (IO-102 + IO-103) in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Kidney Cancer (Renal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (IO-102 + IO-103) in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Head...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (IO-102 + IO-103) in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Solid Tumor Drug Details: PD-L1/IDO (IO102/IO103)...